Keith Campbell, Attorney, Mueting, Raasch & Gebhardt, P.A. to Speak at The Knowledge Group's Event

New York, NY, October 06, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Keith Campbell, Attorney, Mueting, Raasch & Gebhardt, P.A. will speak at the Knowledge Congress’ webcast entitled: “Best Strategies and Practical Tips in Overcoming Biotech Patent Eligibility Rejections Live Webcast.” This event is scheduled for Tuesday, October 24, 2017 @ 3:00 PM to 4:30 PM (ET).

For further details, please visit:
https://www.theknowledgegroup.org/?p=28245

About Keith Campbell

Keith M. Campbell, a shareholder at Mueting, Raasch & Gebhardt, P.A., is a registered patent attorney whose practice focuses on patent preparation and prosecution, due diligence, freedom-to-operate opinions and analysis and portfolio management. Keith represents clients with interests in both domestic and international markets in the areas of biotechnology, chemical, pharmaceutical, materials science, and mechanical arts, whose technologies include medical devices, small molecules, polymers and coatings, cell and tissue culture technologies, immunology, and peptide and nucleic acid technologies. Keith has previously worked as in-house counsel for a Fortune 500 company.

About Mueting, Raasch & Gebhardt, P.A.

Mueting, Raasch & Gebhardt, P.A. (“MRG”) is an intellectual property law firm with expertise in patent preparation, prosecution, and opinions. MRG’s knowledgeable attorneys practice in a wide variety of technology areas including biotechnology, pharmacology, immunology, analytical chemistry and instrumentation, organic chemistry, chemical engineering, material science, mechanical engineering, designs, physics, electrical engineering, electro-mechanical systems, and computer software. MRG is committed to providing their clients with high quality legal work at reasonable rates, and partner with them to tailor their services to cost-effectively meet their needs.

Event Synopsis:

Since its pivotal decisions on Alice Corp. v. CLS Bank last 2014, Assn. for Molecular Pathology v. Myriad Genetics Inc. and Mayo Collaborative Services v. Prometheus Laboratories, Inc. the United States Patent and Trademark Office (USPTO) has been stricter in granting patent eligibility for all types of technology, including biotech patents. Recent rejections under §101 pose an alarming situation for patent applicants, making them more cautious in their succeeding applications.

Listen as a distinguished patent professional team up with The Knowledge Group to provide the audience with the latest issues surrounding §101 eligibility rejections. Speakers will analyze, among other things, recent court decisions and rejections concerning biotech patent applications. They will also offer best practices and strategic tips in overcoming such rejections.

In a live webcast, the speakers will discuss:

Overview of Supreme Court's Decision on Alice Corp. v. CLS Bank, Assn. for Molecular Pathology v. Myriad Genetics Inc. and Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Rejections under §101 since Alice Corp., Myriad and Prometheus
Lessons Learned from Recent Rejections
Steps in Assessing Patent Eligibility for Biotech Patents

· Best Practices and Strategic Tips

About The Knowledge Group/The Knowledge Congress Live Webcast Series

The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/